NCT06948292View on ClinicalTrials.gov

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

PHASE2CompletedINTERVENTIONAL

Enrollment

127

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

August 30, 2024

Study Completion Date

October 30, 2024

Conditions

Chronic Kidney Disease Stages 3-5Diabetic Kidney DiseaseHypertensive Kidney Disease

Interventions

DRUG

QRX-3

phase 2B CKD study

Trial Locations (1)

77504

Neukidney Inc, Pasedena

All Listed Sponsors

lead

Ebima Clifford Okundaye

INDUSTRY